Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
Targets |
Human Endogenous Metabolite
|
---|---|
ln Vitro |
Benzamide, an inhibitor of PARP protects primary cultures of neurons derived from neonatal rat brain against cell death caused by excitatory amino acids. Furthermore, it has recently been demonstrated that benzamide can at least partially shield fetal rat mesencephalic cells in culture from the in vitro effects of METH, including the loss of dopaminergic cells and an increase in reactive gliosis[1]. Benzamide inhibits transformation in a way that is specific to the cell cycle, with the greatest prevention occurring in the early S phase, which is also a feature of the maximum susceptibility to transformation[2].
|
ln Vivo |
Benzamide, a PARP inhibitor, protects C57Bl/6N mice's brains from various neurotoxicities while maintaining body temperature[2]. Neuronal survival and memory during GCI are improved by benzoamide treatment, which dramatically reduces apoptotic neuron count and iNOS expression. Administering 160 mg/kg i.p. of benzamide does not cause hypothermia, and it reaches the central nervous system (CNS) in 30 minutes at concentrations between 0.09 and 0.64 mM, where it exhibits neuroprotection[3].
|
Cell Assay |
The release of the metabolically induced G1/S block is followed by three washings and refeeding with fresh media for ten hours, during which time the carcinogens and benzamide are exposed.
|
Animal Protocol |
C57B1/6N mice (intraperitoneal injection of METH at 2-h intervals; 4 injections of 5 mg/kg, 4 injections of 10 mg/kg, or 2 injections of 20 mg/kg)
160 mg/kg IP, 2 injection by a 4 h interval |
References |
Molecular Formula |
C7H7NO
|
---|---|
Molecular Weight |
121.137
|
Exact Mass |
121.05
|
CAS # |
55-21-0
|
Appearance |
Powder
|
SMILES |
C1=CC=C(C=C1)C(=O)N
|
InChi Key |
KXDAEFPNCMNJSK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C7H7NO/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H2,8,9)
|
Chemical Name |
benzamide
|
Synonyms |
Benzenecarboxamide; Benzamide; Phenylamide
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 24~120 mg/mL (198.1~990.6 mM)
Ethanol : ~24 mg/mL (~198.1 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (24.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (24.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (24.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 8.2549 mL | 41.2746 mL | 82.5491 mL | |
5 mM | 1.6510 mL | 8.2549 mL | 16.5098 mL | |
10 mM | 0.8255 mL | 4.1275 mL | 8.2549 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00534573 | Completed | Drug: Amisulpride, Moclobemide | Clozapine-induced Hypersalivation | Beersheva Mental Health Center | November 2008 | Phase 3 |